1. Home
  2. TG vs ELDN Comparison

TG vs ELDN Comparison

Compare TG & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tredegar Corporation

TG

Tredegar Corporation

HOLD

Current Price

$7.96

Market Cap

353.3M

Sector

Industrials

ML Signal

HOLD

Logo Eledon Pharmaceuticals Inc.

ELDN

Eledon Pharmaceuticals Inc.

HOLD

Current Price

$3.89

Market Cap

300.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TG
ELDN
Founded
1988
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Metal Fabrications
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
353.3M
300.3M
IPO Year
1994
2014

Fundamental Metrics

Financial Performance
Metric
TG
ELDN
Price
$7.96
$3.89
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$8.50
AVG Volume (30 Days)
183.6K
1.1M
Earning Date
05-08-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
151.06
30.67
EPS
0.17
N/A
Revenue
$800,821,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$47.03
N/A
Revenue Growth
8.29
N/A
52 Week Low
$6.25
$1.35
52 Week High
$10.53
$4.60

Technical Indicators

Market Signals
Indicator
TG
ELDN
Relative Strength Index (RSI) 42.39 58.77
Support Level $7.30 $2.52
Resistance Level $8.04 $4.14
Average True Range (ATR) 0.54 0.22
MACD -0.15 -0.02
Stochastic Oscillator 26.24 65.07

Price Performance

Historical Comparison
TG
ELDN

About TG Tredegar Corporation

Tredegar Corp is engaged in the manufacture of aluminum extrusions and polyethylene and polypropylene plastic films. It produces surface protection films, packaging films and films for other markets. The company continues to have two reportable segments: Aluminum Extrusions and High Performance Films. The majority of the revenue is derived form the Aluminum Extrusions segment which produces high-quality, soft and medium strength alloyed aluminum extrusions, custom fabricated and finished, for the building and construction, automotive and transportation, consumer durables goods, machinery and equipment, electrical and renewable energy, and distribution markets.

About ELDN Eledon Pharmaceuticals Inc.

Eledon Pharmaceuticals Inc is a clinical stage biotechnology company using immunology expertise in targeting the CD40 Ligand pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis. Its compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40L, a well-validated biological target that has broad therapeutic potential. It operates as one reportable segment, focused on the development of tegoprubart, to develop therapies to protect transplanted organs and prevent rejection, and to treat ALS.

Share on Social Networks: